

## **SUPPLEMENTARY INFORMATION**

### ***De novo* helical peptides as target sequences for a specific, fluorogenic protein labelling strategy**


Julia Guy<sup>†</sup>, Roselyne Castonguay<sup>†</sup>, Nathalie B. Campos-Reales Pineda<sup>†</sup>,  
Valérie Jacquier<sup>‡</sup>, Karine Caron<sup>†</sup>,  
Stephen W. Michnick<sup>‡</sup>, and Jeffrey W. Keillor<sup>†‡\*</sup>

<sup>†</sup>Département de chimie, <sup>‡</sup>Département de biochimie,  
Université de Montréal,  
Montréal, QC H3C 3J7  
Canada


[jw.keillor@umontreal.ca](mailto:jw.keillor@umontreal.ca)

**Contents:** CD spectra of unlabelled and labelled dC10, tables of primers used for cloning and mutagenesis, fluorescence spectra of fluorogens and dithiolated adducts, and images of negative control cell labelling experiments.

**Figure S1:** Normalised CD spectrum (5 mM sodium phosphate, pH 7.0, 23 °C.) of dC10 after thrombin-mediated cleavage from MBP-dC10



**Figure S2:** Normalised CD spectrum (5 mM sodium phosphate, pH 7.0, 23 °C) of dC10 after labelling with dM10<sup>M</sup>-FITC (**2**) and subsequent thrombin-mediated cleavage from MBP-dC10 (*cf* Figure S1)



**Table S1:** Experimental and predicted helicity values for thrombin-cleaved peptides dC10 and dC10 labelled with dM10<sup>M</sup>-FITC (**2**), determined by CD in 5 mM sodium phosphate, pH 7.0, 23 °C.

Peptide	Experimental mean residue ellipticity <sup>a</sup>	Experimental mean ellipticity <sup>a</sup>	Predicted helicity value (AGADIR) <sup>b</sup>
dC10	17.74	-62.94	27.73 % <sup>c</sup>
dC10-dM10-FITC	18.81	-54.88	

<sup>a</sup> Measured at 222 nm

<sup>b</sup> See references 1 and 2.

<sup>c</sup> Value determined for cleaved peptide at pH 7.0, 23 °C and ionic strength of 0.1. Similar values of 28.90 % and 28.53 % were determined at ionic strength of 0.025, at pH 7.4 and pH 7.0, respectively.

---

<sup>1</sup> Muñoz, V.; Serrano, L. : Development of the Multiple Sequence Approximation Within the AGADIR Model of  $\alpha$ -Helix Formation: Comparison with Zimm–Bragg and Lifson–Roig Formalisms. *Biopolymers* **1997**, *41*, 495-509.

<sup>2</sup> The AGADIR algorithm is available on-line at <http://www.embl-heidelberg.de/Services/serrano/agadir/agadir-start.html>.

**Table S2:** Nucleotide sequences of dC10 helices studied herein. Mutations relative to parent dC10 are underlined. See Table 6 for corresponding amino acid sequences.

Helix Name	Nucleotide sequence
<b>dC10</b>	5'-CTGAGCGCTGCTGAGTGCCTGCTAGAGAAGCTGCATGCAGAGAA GCTGCAGCTAGAGCTGGAGGAAAGTAG-3'
<b>dC10-H2</b>	5'-CTG <u>CAC</u> GCTGCTGAGTGCCTGCTAGAGAAGCTGCATGCAGAGAA GCTGCAGCTAGAGCTGGAGGAAAGTAG-3'
<b>dC10-H7</b>	5'-CTGAGCGCTGCTGAGTGCC <u>CAC</u> GCTAGAGAAGCTGCATGCAGAGAA GCTGCAGCTAGAGCTGGAGGAAAGTAG-3'
<b>dC10-H9</b>	5'-CTGAGCGCTGCTGAGTGCCTGCT <u>CAC</u> GAAGCTGCATGCAGAGAA GCTGCAGCTAGAGCTGGAGGAAAGTAG-3'
<b>dC10-H2H17</b>	5'-CTG <u>CAC</u> GCTGCTGAGTGCCTGCTAGAGAAGCTGCATGCAGAGAA GCT <u>CAC</u> GCTAGAGCTGGAGGAAAGTAG-3'

**Table S3:** Primers used for site-directed mutagenesis.


Mutant dC10 helix	Primer sequence
<b>dC10-H2</b>	5'-GGCTCTCTCGAGCTGC <u>CACG</u> CTGCTGAGTGCGCT-3' 5'-AGCGCACTCAGCAGCGTGCAGCTCGAGAGAGCC-3'
<b>dC10-H7</b>	5'-GCGCTGCTGAGTGCC <u>CACG</u> CTAGAGAAGCTGC-3' 5'-GCAGCTTCTCTAGCGTGGCACTCAGCAGCGC-3'
<b>dC10-H9</b>	5'-GCTGAGTGCGCTGCTC <u>CACG</u> AAGCTGCATGCAGAG-3' 5'-CTCTGCATGCAGCTTCGTGAGCAGCGCACTCAGC-3'
<b>dC10-H2H17</b>	5'-GCATGCAGAGAAGCTC <u>CACG</u> CTAGAGCTGGAGG-3' 5'-CCTCCAGCTCTAGCGT <u>GAG</u> CTTCTCTGCATGC-3' 5'-GGCTCTCTCGAGCTGC <u>CACG</u> CTGCTGAGTGCGCT-3' 5'-AGCGCACTCAGCAGCGTGCAGCTCGAGAGAGCC-3'

**Table S4:** Primers used for cloning of MBP-dC10-R8A9 and MBP-dC10-A9


Mutant dC10 helix	Primer sequence
<b>MBP-dC10-R8A9</b>	5'-TCGAGCTGAGTGCGGCGGAATGTGCGCGTGCAAGCAGC ATGCCGCGAAGCGGCGGCGCGCGGGTGGCAAATGA-3' 5'-AGCTTCATTTGCCACCCGCGCGCGCCGCGCTTCGCGGCAT GCTGCTTCTGCACGCGCACATTCCGCCGCACTCAGC-3'
<b>MBP-dC10-A9</b>	5'- TCGAGCTGAGTGCGGCGGAATGTGCGGCAGCAGAAGCA GCATGCCGCGAAGCGGCGGCGCGCGGGTGGCAAATGA-3' 5'- AGCTTCATTTGCCACCCGCGCGCGCCGCGCTTCGCGGC ATGCTGCTTCTGCTGCCGCACATTCCGCCGCACTCAGC-3'

**Figure S3:** **A:** Fluorogenic reactions of fluorogens dM10<sup>M</sup>-FITC (**2**) and dM10<sup>M</sup>-dansyl (**3**) with excess MPA in 50 mM HEPES (pH 7.5) with 5 % DMSO. **B:** Fluorescence spectra recorded before and after addition reactions of 2.5  $\mu$ M **2** ( $\lambda_{\text{exc}} = 494$  nm,  $\lambda_{\text{fl}} = 517$  nm) and 75  $\mu$ M **3** ( $\lambda_{\text{exc}} = 331$  nm,  $\lambda_{\text{fl}} = 551$  nm), showing the fluorescence enhancements reported in Table 5.

**A**



**B**



**Figure S4:** Negative control experiment for labelling of EGF receptors. **A:** Phase-contrast image of HEK 293 cells expressing EGFR (*not* tagged with dC10 sequence) **B:** Confocal image after incubation with 20  $\mu\text{M}$  dM10<sup>M</sup>-FITC (**2**) for 20 minutes, showing *no* cell surface labelling. Non-specific green fluorescence is attributed to dead cell debris. **C:** Red fluorescent image using the same brightness and contrast settings as B, after incubation with rhodamine-labelled EGF, showing proper expression of EGFR on the cell surface.

